MHRAsafety guidance72% confidence
Guidance: AI Airlock Sandbox Phase 2 Programme Report
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Roche.
Regulatory Analysis
The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.
Supporting Context
- Therapeutic area
- Obesity · Peptide Therapy
- Sub-indication
- General
Related signal: Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026